ClinicalTrials.gg
CompletedNCT04626297Updated Oct 17, 2023Results posted

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

A Phase 3 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 85 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
12th of 24
254 · median 252
Started
2020
with 3 others
Phase 3
17 of 24
2 open now
Registered
9th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 12th largest by enrollment, is one of 4 that started in 2020, is one of 17 in phase 3, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
  • Skin Diseases
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic atopic dermatitis (AD) according to American Academy of Dermatology Consensus Criteria that has been present for ≥1 year before screening.
  • Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit.
  • Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit.
  • ≥10% Body Surface Area (BSA) of AD involvement at the baseline visit.
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.
  • Have not received any tetanus-containing vaccine within approximately 5 years of baseline.
  • Have never received a meningococcal conjugate vaccine or have received not more than 1 prior MCV dose at least 4 years prior to baseline, of a vaccine containing 1 or more meningococcal serogroups (serogroups A, C, W, Y).
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    • a. Female participants of : must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of study drug. Women of non-childbearing potential (non-WOCBP) may participate without any contraception requirements.
    • b. Male participants are not required to use any contraception except in compliance with specific local government study requirements.

Exclusion criteria

Exclusion Criteria:

  • Recurring herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis
  • Evidence of active or chronic hepatitis
  • History of (HIV) infection or positive HIV serology.
  • Presence of skin comorbidities that may interfere with study assessments.
  • History of , including mycosis fungoides, within 5 years before screening, except completely treated in situ carcinoma of the cervix or completely treated and resolved non- squamous or basal cell carcinoma of the skin.
  • Uncontrolled chronic disease that might require bursts of oral , e.g., co-morbid severe uncontrolled asthma.
  • Have a prior history of Guillain-Barre syndrome.
  • Allergic to latex.
  • History of past vaccination allergy or Arthus-type .
  • Have an uncontrolled seizure disorder.
  • Have known hypogammaglobulinemia or a screening serum immunoglobulin G (IgG) or immunoglobulin A (IgA) concentration less than the lower limit of the reporting laboratory's reference range.
  • Treated with topical corticosteroids (TCS), calcineurin inhibitors, or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit.
  • Treated with the following prior to baseline visit:

    • a. An drug within 8 weeks or within 5 half-lives (if known), whichever is longer
    • b. B Cell-depleting biologics, including rituximab, within 6 months
    • c. Other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer
  • Received a Bacillus Calmette-Guerin (BCG) vaccination or treatment within 12 months of screening, or treated with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study.
  • A to the Tdap vaccine or mean corpuscular volume (MCV).
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Participants received a loading dose of 500 milligram (mg) lebrikizumab injection administered subcutaneously (SC) at baseline and week 2, and 250 mg once every two weeks (Q2W) from week 4 to 14.

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Participants received placebo SC injection Q2W from baseline to week 14.

    Drug: Placebo

Interventions

  • Given SC

    Also known as: LY3650150, DRM06

  • DrugPlacebo

    Given SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration

    Booster response to tetanus toxoid is defined as: ≥4-fold increase in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration if the pre-vaccination level was \>0.10 International units per milliliter (IU/mL) and ≤2.7 IU/mL; OR ≥2-fold increase in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination level was \>2.7 IU/mL; OR ≥4-fold increase in anti-tetanus toxoid IgG antibody concentration and a post-vaccination level ≥0.10 IU/mL if the pre-vaccination level was ≤0.10 IU/mL

    Time frame: Week 16

  2. Percentage of Participants Who Have Positive Antibody Response to Meningococcus C Antigen 4 Weeks After Meningococcal Conjugate Vaccine (MCV) Administration

    Positive antibody response to Meningococcus C antigen as measured by group C serum bactericidal antibodies is defined as: post-vaccination rabbit complement serum bactericidal assay (rSBA) titer ≥4 times the lower limit of quantitation (LLOQ), if the pre-vaccination rSBA titer is less than the LLOQ; OR post-vaccination rSBA titer ≥4 times the pre-vaccination titer, if the pre-vaccination rSBA titer is greater than or equal to the LLOQ.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline

    The IGA measures the investigator's global assessment of the participants overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. Markov Chain Monte Carlo Multiple Imputation (MCMC-MI) was used to handle missing data.

    Time frame: Week 16

  2. Percentage of Participants Achieving a ≥75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-75)

    The EASI-75 is defined as a ≥ 75% improvement from baseline in the EASI score. EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. MCMC-MI was used to handle missing data.

    Time frame: Week 16

  3. Percentage of Participants Achieving ≥90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-90)

    The EASI-90 is defined as a ≥ 90% improvement from baseline in the EASI score. EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. MCMC-MI was used to handle missing data.

    Time frame: Week 16

  4. Percentage of Participants Achieving ≥4-Point Improvement From Baseline in Pruritus Numeric Rating Scale (NRS) Score

    The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." MCMC-MI was used to handle missing data.

    Time frame: Week 16

  5. Change From Baseline in Percent Body Surface Area (BSA)

    The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of body surface area. It was assessed for 4 body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100%. BSA was calculated using the participant's palm, 1 palm = 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 for head and neck (10%), 20 for upper extremities (20%), 30 for trunk, including axilla and groin (30%), and 40 for lower extremities, including buttocks (40%). Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Sleep-Loss Score

    Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicate a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary, and the week 16 score was calculated by averaging the daily scores from the previous 7 days and the average score was used to compute a change from baseline. MCMC-MI was used to handle missing data.

    Time frame: Baseline, Week 16

07

Results

Posted Aug 28, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboLebrikizumab 250 mg
Started127127
Received at least 1 dose of study drug127127
Completed88113
Not completed3914
Withdrew: Adverse event53
Withdrew: Lost to follow-up73
Withdrew: Protocol violation51
Withdrew: Withdrawal by subject206
Withdrew: Sponsor decision21

Outcome measures

PrimaryPercentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration

Booster response to tetanus toxoid is defined as: ≥4-fold increase in anti-tetanus toxoid immunoglobulin G (IgG) antibody concentration if the pre-vaccination level was \>0.10 International units per milliliter (IU/mL) and ≤2.7 IU/mL; OR ≥2-fold increase in anti-tetanus toxoid IgG antibody concentration if the pre-vaccination level was \>2.7 IU/mL; OR ≥4-fold increase in anti-tetanus toxoid IgG antibody concentration and a post-vaccination level ≥0.10 IU/mL if the pre-vaccination level was ≤0.10 IU/mL

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration73.473.6
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Risk difference (rd): 0.3 · 90% CI -10.2 to 11.2
PrimaryPercentage of Participants Who Have Positive Antibody Response to Meningococcus C Antigen 4 Weeks After Meningococcal Conjugate Vaccine (MCV) Administration

Positive antibody response to Meningococcus C antigen as measured by group C serum bactericidal antibodies is defined as: post-vaccination rabbit complement serum bactericidal assay (rSBA) titer ≥4 times the lower limit of quantitation (LLOQ), if the pre-vaccination rSBA titer is less than the LLOQ; OR post-vaccination rSBA titer ≥4 times the pre-vaccination titer, if the pre-vaccination rSBA titer is greater than or equal to the LLOQ.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Have Positive Antibody Response to Meningococcus C Antigen 4 Weeks After Meningococcal Conjugate Vaccine (MCV) Administration
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Who Have Positive Antibody Response to Meningococcus C Antigen 4 Weeks After Meningococcal Conjugate Vaccine (MCV) Administration7586.9
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Risk difference (rd): 12.2 · 90% CI 2.5 to 22.0
SecondaryPercentage of Participants Achieving an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline

The IGA measures the investigator's global assessment of the participants overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. Markov Chain Monte Carlo Multiple Imputation (MCMC-MI) was used to handle missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Achieving an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline18.9 (11.4 to 26.3)40.6 (31.8 to 49.4)
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.7 · 95% CI 10.3 to 33.2
SecondaryPercentage of Participants Achieving a ≥75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-75)

The EASI-75 is defined as a ≥ 75% improvement from baseline in the EASI score. EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. MCMC-MI was used to handle missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-75)
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Achieving a ≥75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-75)32.7 (23.5 to 41.9)58.0 (49.1 to 66.9)
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 25.3 · 95% CI 12.6 to 38
SecondaryPercentage of Participants Achieving ≥90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-90)

The EASI-90 is defined as a ≥ 90% improvement from baseline in the EASI score. EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. MCMC-MI was used to handle missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-90)
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Achieving ≥90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI-90)18.9 (11.3 to 26.4)39.2 (30.5 to 47.9)
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.3 · 95% CI 9.0 to 31.6
SecondaryPercentage of Participants Achieving ≥4-Point Improvement From Baseline in Pruritus Numeric Rating Scale (NRS) Score

The Pruritus NRS is an 11-point scale used by participants to rate their worst itch severity over the past 24 hours, with 0 indicating "No itch" and 10 indicating "Worst itch imaginable." MCMC-MI was used to handle missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥4-Point Improvement From Baseline in Pruritus Numeric Rating Scale (NRS) Score
percentage of participantsPlaceboLebrikizumab 250 mg
Percentage of Participants Achieving ≥4-Point Improvement From Baseline in Pruritus Numeric Rating Scale (NRS) Score33.2 (22.6 to 43.8)51.7 (41.2 to 62.3)
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Cochran-Mantel-Haenszel · p = 0.138 · Risk difference (rd): 11.9 · 95% CI -3.8 to 27.5
SecondaryChange From Baseline in Percent Body Surface Area (BSA)

The BSA assessment estimates the extent of disease or skin involvement with respect to AD and is expressed as a percentage of body surface area. It was assessed for 4 body regions: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100%. BSA was calculated using the participant's palm, 1 palm = 1% with estimates of the number of palms it takes to cover the affected AD area. Maximum number of palms were 10 for head and neck (10%), 20 for upper extremities (20%), 30 for trunk, including axilla and groin (30%), and 40 for lower extremities, including buttocks (40%). Percent of BSA for a body region = total number of palms in a body region \* % surface area equivalent to 1 palm. Overall percent BSA for an individual is arithmetic mean of % BSA of all 4 body regions and ranges from 0% to 100% with higher values representing greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline in Percent Body Surface Area (BSA)
percentage of body surface areaPlaceboLebrikizumab 250 mg
Change From Baseline in Percent Body Surface Area (BSA)-19.34 ± 1.882-27.55 ± 1.719
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · Mixed Models Analysis · p = <0.001 · Ls mean difference: -8.21 · 95% CI -13.04 to -3.39The mixed model repeated measures (MMRM) included treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, geographic region, age group, baseline IGA score as fixed factors.
SecondaryChange From Baseline in Sleep-Loss Score

Sleep Loss due to interference of itch will be assessed by the participant. Participants rate their interference of itch on sleep based on a 5-point Likert scale \[0 (not at all) to 4 (unable to sleep at all)\]. Higher scores indicate a greater impact and worse outcome. Assessments will be recorded daily by the participant using an electronic diary, and the week 16 score was calculated by averaging the daily scores from the previous 7 days and the average score was used to compute a change from baseline. MCMC-MI was used to handle missing data.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Sleep-Loss Score
score on a scalePlaceboLebrikizumab 250 mg
Change From Baseline in Sleep-Loss Score-0.87 ± 0.122-1.35 ± 0.107
Statistical analysis
  • Placebo vs Lebrikizumab 250 mg · ANCOVA · p = 0.001658 · Ls mean difference: -0.48 · 95% CI -0.8 to -0.2

Adverse events

Collected over Baseline Up To Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/127 (0%)1/127 (0.8%)43/127 (33.9%)
Lebrikizumab 250 mg0/127 (0%)1/127 (0.8%)47/127 (37%)
Most frequent serious events
Most frequent serious events
EventPlaceboLebrikizumab 250 mg
Breast cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1271/127
Dermatitis atopicSkin and subcutaneous tissue disorders1/1270/127
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPlaceboLebrikizumab 250 mg
Dermatitis atopicSkin and subcutaneous tissue disorders8/1276/127
Covid-19Infections and infestations5/1277/127
NasopharyngitisInfections and infestations3/1274/127
HeadacheNervous system disorders1/1274/127
ConjunctivitisInfections and infestations0/1273/127
Conjunctivitis allergicEye disorders0/1272/127
Chest painGeneral disorders0/1272/127
FatigueGeneral disorders1/1272/127
Injection site bruisingGeneral disorders0/1272/127
Otitis externaInfections and infestations0/1272/127

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboLebrikizumab 250 mgTotal
Mean35.9 ± 10.1435.2 ± 11.5435.6 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLebrikizumab 250 mgTotal
Female6772139
Male6055115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLebrikizumab 250 mgTotal
Hispanic or Latino454994
Not Hispanic or Latino8277159
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLebrikizumab 250 mgTotal
American Indian or Alaska Native011
Asian181634
Native Hawaiian or Other Pacific Islander123
Black or African American292958
White7274146
More than one race224
Unknown or Not Reported538
Region of Enrollment
Region of Enrollment(Participants)PlaceboLebrikizumab 250 mgTotal
United States127127254
08

Study locations

85 sites
  • Clinical Research Center of Alabama- Birmingham
    Birmingham, Alabama 35244, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • Wallace Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center For Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Axon Clinical Research
    Inglewood, California 90301, United States
  • Sunwise Clinical Research
    Lafayette, California 94549, United States
  • Avance Trials
    Laguna Niguel, California 92677, United States
  • Keck School of Medicine University of Southern California
    Los Angeles, California 90033, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • LA Universal Research Center, INC
    Los Angeles, California 90057, United States
  • Ablon Skin Institute and Research Center
    Manhattan Beach, California 90266, United States
  • Dermatology Clinical Trials
    Newport Beach, California 92660, United States
  • Cura Clinical Research
    Palmdale, California 93551, United States
  • MD Strategies Research Centers MDSRC
    San Diego, California 92119, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • Synergy Dermatology
    San Francisco, California 94132, United States
  • Care Access Research
    San Jose, California 95117, United States
  • San Luis Dermatology & Laser Clinic
    San Luis Obispo, California 93405, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • IMMUNOe International Research Centers
    Centennial, Colorado 80112, United States
  • Asthma and Allergy Associates, PC
    Colorado Springs, Colorado 80907-6231, United States
  • Florida Academic Centers Research and Education, LLC
    Coral Gables, Florida 33134, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • The Community Research of South Florida
    Hialeah, Florida 33016, United States
  • Solutions Through Advanced Research
    Jacksonville, Florida 32256, United States
  • C&R Research Services USA
    Kendall, Florida 33183, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Sanchez Clinical Research Inc
    Miami, Florida 33157, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • Florida Research Center, Inc
    Miami, Florida 33174, United States
  • Riverchase Dermatology and Cosmetic Surgery
    Pembroke Pines, Florida 33028, United States
  • Tampa General Hospital
    Tampa, Florida 33612, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Georgia Skin & Cancer Clinic
    Savannah, Georgia 31419, United States
  • Sneeze, Wheeze, & Itch Associates LLC
    Normal, Illinois 61761, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Kansas Medical Clinic, an Elligo Health Research, Inc.
    Shawnee Mission, Kansas 66216, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66614, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • Tulane Univ School of Med
    New Orleans, Louisiana 70112, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Oakland Dermatology
    Auburn Hills, Michigan 48326, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Advanced Dermatology of the Midlands
    Omaha, Nebraska 68144, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Skin Laser and Surgery Specialists, a Division of Schweiger Dermatology
    Hackensack, New Jersey 07601, United States
  • JUVA Skin & Laser Center
    New York, New York 10022-3350, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Unity Clinical Research
    Oklahoma City, Oklahoma 73118, United States
  • Central States Research
    Tulsa, Oklahoma 74136, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Peak Research LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • AAPRI Clinical Research Institute
    Warwick, Rhode Island 02886, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Arlington Research Center, Inc
    Arlington, Texas 76011, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research
    Dripping Springs, Texas 78620, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Laredo Dermatology Associates P.A.
    Laredo, Texas 78041, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Velocity Clinical Research - Woseth Dermatology
    Salt Lake City, Utah 84117, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Aug 2022, 20 months.

Results were first posted in Aug 2023, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
Nov 17, 2020
Primary completionActual
Aug 3, 2022
CompletionActual
Sep 30, 2022
Results first posted
Aug 28, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04626297
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Nov 17, 2020
Primary completion
Aug 3, 2022
Completion
Sep 30, 2022
Results posted
Aug 28, 2023
Last update
Oct 17, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion